The global panhematin market size is projected to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is rising incidence of blood disorders across the globe.
Panhematin is a germ-free lyophilized powder, which is appropriate for intravenous administration. It is given by injection into the vein as directed by physician. The dosage is based on weight, medical conditions, and response to therapy. Panhematin provide therapeutic benefits in treating patients with pancreatitis.
Panhematin is use for intravenous infusion only. The standard dose of panhematin in clinical practice is three to four mg/kg/day. Repeated dose is given in more severe cases, which is no earlier than every 12 hours. The dose may be administered directly from the vial over a period of at least 30 minutes. After the injection, vein is flushed by using 100 mL of 0.9% NaCl.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing demand in various regions around the globe due to the rising cases of porphyria related to the menstrual cycle in women is projected to drive the market demand in the projected timeline
- Growing health concerns is anticipated to propel the market expansion during the forecast period.
- The COVID-19 pandemic has increased the burden on the healthcare sector, positively influencing the market growth.
- Side effects such as swelling, rapid weight gain, and shortness in breathing can hinder the market growth during the forecast period.
- Panhematin cannot be stored at home as it is usually given in hospitals or clinics, restricting the market expansion during the forecast period.
- Rising R&D investment is projected to create lucrative opportunities for the market growth during the forecast period.
Scope of Panhematin Market Report
The report on the global panhematin market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes
|
Details
|
Report Title
|
Panhematin Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
Base Year
|
2020
|
Historic Data
|
2018–2019
|
Forecast Period
|
2021–2028
|
Segmentation
|
Types (350mg and 313mg), Applications (Hospitals and Pharmacies)
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
Key Players Covered in the Report
|
Abbot
|
Panhematin Market Segment Insights
313 mg segment is projected to account for a large market share
On the basis of types, the panhematin market is bifurcated into 350 mg and 313 mg. The 313 mg segment is expected to account for a major market share during the forecast period. The product contains no preservatives. When panhematin is mixed as directed with sterile water for injection, each 43 ml provides the equivalent of approximately 301 mg hematin.
Each dispensing vial of panhematin contains the equivalent of 313 mg hemin, 215 mg sodium carbonate, and 300 mg of sorbitol. The pH can be adjusted with hydrochloric acid. The dosage is based on your weight, medical conditions, and response to therapy.
Hospitals segment is anticipated to register a substantial CAGR
In terms of applications, the panhematin market is classified as hospitals and pharmacies.
The hospitals segment is anticipated to expand at a substantial CAGR during the forecast period. Monitoring of the patient is required after administration of panhematin injection. It is given by injection into a vein by professional practitioner in hospitals. Before using panhematin, one need to consult doctor related to allergies as this product may consist of inactive ingredients, which can cause allergic reactions or other problems.
North America is anticipated to dominate the market
On the basis of regions, the panhematin market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market during the forecast period. The regional market growth is attributed to adoption of latest technology for manufacturing of panhematin medicine. Moreover, the presence of major industry players in the countries such as the US and Canada is expected to proliferate the growth of the market in the region.
The market in Asia Pacific is anticipated to exhibit a high CAGR during the forecast period. Increasing incidence of blood-related disorders is driving the growth of the market in the region. Rising number of hospitals owing to increasing investment in the healthcare infrastructure is propelling the regional market growth.
Segments
The global panhematin market has been segmented on the basis of
Types
Applications
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
Competitive Landscape
Key players competing in the panhematin market include Abbot.
